Fetal assessment before and after dosing with buprenorphine or methadone

Addiction

Volumn 107, Issue SUPPL.1, 2012, Pages 36-44

  Salisbury, Amy L ^a   Coyle, Mara G ^a   O'Grady, Kevin E ^b   Heil, Sarah H ^c   Martin, Peter R ^d   Stine, Susan M ^e   Kaltenbach, Karol ^f   Weninger, Manfred ^g   Jones, Hendrée E ^h,i  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ RTI INTERNATIONAL   (United States)

Author keywords

Biophysical profile; Fetal; Heart rate; Opiates

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BIOPHYSICS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FETUS; FETUS HEART RATE; FETUS MONITORING; FETUS MOVEMENT; GESTATIONAL AGE; HUMAN; METHODOLOGY; MULTICENTER STUDY; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BIOPHYSICAL PROCESSES; BUPRENORPHINE; DOUBLE-BLIND METHOD; FEMALE; FETAL MONITORING; FETAL MOVEMENT; FETUS; GESTATIONAL AGE; HEART RATE, FETAL; HUMANS; INFANT, NEWBORN; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PREGNANCY; PREGNANCY COMPLICATIONS; YOUNG ADULT;

EID: 84868112909     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04037.x     Document Type: Article

References (38)

1. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fisher G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008; 103: 1429-1440.
2. Jones H. E., O'Grady K. E., Malfi D., Tuten M. Methadone maintenance versus methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17: 372-386.
3. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998; 25: 139-151.
4. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisholm C. A., Choo R. E. etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10.
5. Fischer G., Johnson R. E., Eder H., Jagsch R., Peternell A., Weninger M. etal. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000; 95: 239-244.
6. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S., Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82: 250-257.
7. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M. etal. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275-281.
8. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. etal. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-2331.
9. Nanovskaya T. N., Nekhayeva I. A., Hankins G. D., Ahmed M. S. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol 2008; 198: 126 e1-1264.
10. Zharikova O. L., Deshmukh S. V., Nanovskaya T. N., Hankins G. D., Ahmed M. S. The effect of methadone and buprenorphine on human placental aromatase. Biochem Pharmacol 2006; 71: 1255-1264.
11. Concheiro M., Jones H. E., Johnson R. E., Choo R., Shakleya D. M., Huestis M. A. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther Drug Monit 2010; 32: 206-215.
12. de Castro A., Jones H. E., Johnson R. E., Gray T. R., Shakleya D. M., Huestis M. A. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. Clin Chem 2011; 57: 449-458.
13. Flynn A. M., Kelly J., Mansfield H., Needham P., O'Conor M., Viegas O. A randomized controlled trial of non-stress antepartum cardiotocography. Br J Obstet Gynaecol 1982; 89: 427-433.
14. Lenstrup C., Haase N. Predictive value of antepartum fetal heart rate non-stress test in high-risk pregnancy. Acta Obstet Gynecol Scand 1985; 64: 133-138.
15. Lyons E. R., Bylsma-Howell M., Shamsi S., Towell M. E. A scoring system for nonstressed antepartum fetal heart rate monitoring. Am J Obstet Gynecol 1979; 133: 242-246.
16. Manning F. A., Platt L. D., Sipos L. Antepartum fetal evaluation: development of a fetal biophysical profile. Am J Obstet Gynecol 1980; 136: 787-795.
17. Manning F. A., Snijders R., Harman C. R., Nicolaides K., Menticoglou S., Morrison I. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. Am J Obstet Gynecol 1993; 169: 755-763.
18. Bardakci M., Balci O., Acar A., Colakoglu M. C. Comparison of modified biophysical profile and doppler ultrasound in predicting the perinatal outcome at or over 36 weeks of gestation. Gynecol Obstet Invest 2010; 69: 245-250.
19. Anyaegbunam A., Tran T., Jadali D., Randolph G., Mikhail M. S. Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests. Gynecol Obstet Invest 1997; 43: 25-28.
20. Schmid M., Kuessel L., Klein K., Metz V., Fischer G., Krampl-Bettelheim E. First-trimester fetal heart rate in mothers with opioid addiction. Addiction 2010; 105: 1265-1268.
21. Jansson L. M., Dipietro J. A., Velez M., Elko A., Knauer H., Kivlighan K. T. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med 2009; 22: 29-35.
22. Wittmann B. K., Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict 1991; 26: 213-218.
23. Wouldes T. A., Roberts A. B., Pryor J. E., Bagnall C., Gunn T. R. The effect of methadone treatment on the quantity and quality of human fetal movement. Neurotoxicol Teratol 2004; 26: 23-34.
24. Cejtin H. E., Mills A., Swift E. L. Effect of methadone on the biophysical profile. J Reprod Med 1996; 41: 819-822.
25. Jansson L. M., Dipietro J. A., Velez M., Elko A., Williams E., Milio L. etal. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2011; 33: 240-243.
26. Jones H. E., Fischer M. D., Heil S. H., Kaltenbach K., Martin P. R., Coyle M. G. etal. Maternal Opioid Treatment: Human Experimental Research (MOTHER)-approach, issues, and lessons learned. Addiction 2012; 107 (Suppl. 1): 28-35.
27. Manning F. A. Dynamic ultrasound-based fetal assessment: the fetal biophysical profile score. Clin Obstet Gynecol 1995; 38: 26-44.
28. National Institute of Child Health and Human Development Research Planning Workshop, Electronic fetal heart rate monitoring: research guidelines for interpretation, Am J Obstet Gynecol 1997; 177: 1385-1390.
29. Macones G. A., Hankins G. D., Spong C. Y., Hauth J., Moore T. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112: 661-666.
30. Park Y. S., Koh S. K., Hoh J. K., Park M. I. Difference of fetal heart rate accelerations based on 10 and 15 beats per minute. J Obstet Gynaecol Res 2010; 36: 291-295.
31. Buss C., Davis E. P., Class Q. A., Gierczak M., Pattillo C., Glynn L. M. etal. Maturation of the human fetal startle response: evidence for sex-specific maturation of the human fetus. Early Hum Dev 2009; 85: 633-638.
32. Dyer K. R., Foster D. J., White J. M., Somogyi A. A., Menelaou A., Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther 1999; 65: 685-694.
33. Petrikovsky B. M., Kaplan G. P. Diurnal non-stress test variations in healthy term fetuses. A call for evening appointments for fetal testing. Early Hum Dev 1996; 44: 127-130.
34. Archie C. L., Lee M. I., Sokol R. J., Norman G. The effects of methadone treatment on the reactivity of the nonstress test. Obstet Gynecol 1989; 74: 254-255.
35. Szeto H. H. Effects of narcotic drugs on fetal behavioral activity: acute methadone exposure. Am J Obstet Gynecol 1983; 146: 211-216.
36. Umans J. G., Szeto H. H. Effects of opiates on fetal behavioral activity in utero. Life Sci 1983; 33: 639-642.
37. Dinges D. F., Davis M. M., Glass P. Fetal exposure to narcotics: neonatal sleep as a measure of nervous system disturbance. Science 1980; 209: 619-621.
38. Hutchings D. E. Methadone and heroin during pregnancy: a review of behavioral effects in human and animal offspring. Neurobehav Toxicol Teratol 1982; 4: 429-434.